Bone matrix mineralization increases with age and remains elevated after Teriparatide treatment in WNT1 or PLS3 mutation-related low-turnover osteoporosis: A transiliac bone biopsy study

• Nadja Fratzl-Zelman,
• Katherine Wesseling-Perry,
• Riika E. Mäkitie,
• Paul Roschger,
• Jochen Zwerina,
• Ville-Valtteri Välimäki,
• Christine M. Laine,
• Matti J. Välimäki,
• Renata C. Pereira,
• Outi Mäkitie

Affiliations

Nadja Fratzl-Zelman

Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of OEGK and AUVA Trauma Centre Meidling, 1st Medical Department Hanusch Hospital, Vienna, Austria; Corresponding author.

Katherine Wesseling-Perry

Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, United States

Riika E. Mäkitie

Folkhälsan Institute of Genetics and University of Helsinki, Helsinki, Finland

Paul Roschger

Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of OEGK and AUVA Trauma Centre Meidling, 1st Medical Department Hanusch Hospital, Vienna, Austria

Jochen Zwerina

Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of OEGK and AUVA Trauma Centre Meidling, 1st Medical Department Hanusch Hospital, Vienna, Austria

Ville-Valtteri Välimäki

Department of Orthopaedics and Traumatology, University of Helsinki and Jorvi Hospital, Helsinki University Hospital, Espoo, Finland

Christine M. Laine

Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Department of Endocrinology, Institute of Medicine, Sahlgrenska University Hospital and University of Gothenburg, Gothenburg, Sweden

Matti J. Välimäki

Division of Endocrinology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland

Renata C. Pereira

Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, United States

Outi Mäkitie

Folkhälsan Institute of Genetics and University of Helsinki, Helsinki, Finland; Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland